Conclusions: A previous history of MI places patients with recent ACS at high risk for recurrent MACE and death. Alirocumab reduced the relative risks of these events consistently in patients with or without previous MI, but with numerically greater absolute benefit in the former subgroup.
Share
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35631530/
Statins are the first-line treatment for familial hypercholesterolemia (FH), but response is highly variable due to genetic and nongenetic factors. Here, we explored the association between response and genetic variability...
Conclusion: The deleterious variant ABCC1 rs45511401 enhanced LDL-c response in Brazilian FH patients. As such, this variant might be a promising candidate for the individualization of statin therapy.
Share
Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35621864/
Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to...
Conclusion: In AMI patients, early initiation of evolocumab therapy within 24 h of primary PCI suppressed the increase in lipoprotein(a) levels within 4 weeks, regardless of baseline levels and characteristics.
Share
AFM-based nanoindentation indicates an impaired cortical stiffness in the AAV-PCSK9 DY atherosclerosis mouse model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35648220/
Investigating atherosclerosis and endothelial dysfunction has mainly become established in genetically modified ApoE -/- or LDL-R -/- mice transgenic models. A new AAV-PCSK9DY DY mouse model with no genetic modification...
Conclusion: Our results demonstrate that this model is highly suitable and represents a good alternative to the commonly used transgenic mouse models for studying atherosclerosis and other vascular pathologies.
Share
SORBS2 as a molecular target for atherosclerosis in patients with familial hypercholesterolemia - Journal of Translational Medicine
Source : https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03381-z
Background Familial hypercholesterolemia (FH) is a metabolic disease in which patients are prone to develop premature atherosclerosis (AS). Sorbin and SH3 Domain Containing 2 (SORBS2) is known to play a...
Conclusions: SORBS2 regulates lipid-induced inflammation and foam cell formation, and is a potential therapeutic target for hypercholesterolemia.
Share